Q1 Earnings Forecast for TARS Issued By William Blair

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown expects that the company will earn ($0.06) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at $0.32 EPS, Q3 2026 earnings at $0.56 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $1.62 EPS.

Several other equities analysts have also commented on the company. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Barclays decreased their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Guggenheim reissued a “buy” rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday. Finally, HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $61.33.

Tarsus Pharmaceuticals Trading Up 3.1 %

TARS opened at $42.56 on Thursday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The stock has a market cap of $1.63 billion, a PE ratio of -11.17 and a beta of 1.01. The business has a 50 day moving average of $51.31 and a 200-day moving average of $43.00.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million.

Institutional Trading of Tarsus Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Toronto Dominion Bank purchased a new stake in Tarsus Pharmaceuticals in the fourth quarter worth approximately $105,714,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter valued at $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Tarsus Pharmaceuticals by 18.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company’s stock valued at $3,866,000 after acquiring an additional 10,991 shares during the period. Finally, Woodline Partners LP boosted its position in Tarsus Pharmaceuticals by 52.3% in the fourth quarter. Woodline Partners LP now owns 108,986 shares of the company’s stock worth $6,035,000 after purchasing an additional 37,417 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.